Agendia

Netherlands
Midlum, Friesland, The Netherlands, 1098 XH

Company profile

Agendia company profile

Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

Business identity

Contact email
[email protected]
Phone number
(204) 621-500_
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$50,000+
Founded
2003-01-01, Year

Headquarters

Postal code
1098 XH
Country code
NL
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Private Equity
Funding rounds
9
Total equity funding
$157M
Last funding
Private Equity / $35M / 2018-07-25
Last equity funding
Private Equity / $35M
Investors
12
Lead investors
3
Founders
2
Articles
105

Founders and investors

Founders

Bernhard SixtRene Bernards

Lead investors

Athyrium Capital Management LPDebiopharm GroupNorgine Ventures

Investors

ArdianAthyrium Capital Management LPDebiopharm GroupGilde HealthcareING Group